Serena Di Cosimo

10.6k total citations · 2 hit papers
181 papers, 5.0k citations indexed

About

Serena Di Cosimo is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Serena Di Cosimo has authored 181 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Oncology, 79 papers in Cancer Research and 52 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Serena Di Cosimo's work include HER2/EGFR in Cancer Research (72 papers), Breast Cancer Treatment Studies (55 papers) and Cancer Treatment and Pharmacology (43 papers). Serena Di Cosimo is often cited by papers focused on HER2/EGFR in Cancer Research (72 papers), Breast Cancer Treatment Studies (55 papers) and Cancer Treatment and Pharmacology (43 papers). Serena Di Cosimo collaborates with scholars based in Italy, Spain and United States. Serena Di Cosimo's co-authors include José Baselga, Marta Guzmán, Joaquı́n Arribas, Maurizio Scaltriti, Javier Cortés, Federico Rojo, Paolo Carlini, G. Ferretti, Judit Anido and Santiago Ramón y Cajal and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Serena Di Cosimo

171 papers receiving 4.9k citations

Hit Papers

Expression of p95HER2, a Truncated Form of the HER2 Recep... 2007 2026 2013 2019 2007 2008 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
    2007 659 citations Maurizio Scaltriti, Marta Guzmán et al. profile →
  2. NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
    2008 626 citations Violeta Serra, Ben Markman et al. Cancer Research profile →

Peers

Serena Di Cosimo
Beth Overmoyer United States
Kan Yonemori Japan
Nina J. Karlin United States
Shenghui Tang United States
Ferry A.L.M. Eskens Netherlands
Montserrat Muñoz-Mateu Spain
Robert Justice United States
Marc Espié France
Marek Z. Wojtukiewicz Poland
Erica L. Mayer United States
Beth Overmoyer United States
Serena Di Cosimo
Citations per year, relative to Serena Di Cosimo Serena Di Cosimo (= 1×) peers Beth Overmoyer

Countries citing papers authored by Serena Di Cosimo

Since Specialization
Citations

This map shows the geographic impact of Serena Di Cosimo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serena Di Cosimo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serena Di Cosimo more than expected).

Fields of papers citing papers by Serena Di Cosimo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serena Di Cosimo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serena Di Cosimo. The network helps show where Serena Di Cosimo may publish in the future.

Co-authorship network of co-authors of Serena Di Cosimo

This figure shows the co-authorship network connecting the top 25 collaborators of Serena Di Cosimo. A scholar is included among the top collaborators of Serena Di Cosimo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serena Di Cosimo. Serena Di Cosimo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Russo, M., Giulia Bertolini, Vera Cappelletti, et al.. (2025). Augmentation-based deep learning for identification of circulating tumor cells. Computers in Biology and Medicine. 199. 111333–111333.
2.
3.
Pérez-García, José Manuel, Meritxell Bellet, Miguel Gil‐Gil, et al.. (2025). Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial. ESMO Open. 10(7). 105309–105309.
4.
Appierto, Valentina, Elena Tamborini, Paola Tiberio, et al.. (2025). Circulating tumor DNA to anticipate loco-regional recurrence in early-stage breast cancer: a proof-of-concept study. Frontiers in Oncology. 15. 1621322–1621322.
5.
6.
Ciniselli, Chiara Maura, Paolo Verderio, Paolo Baili, et al.. (2024). Clinical and Biological Significance of HER2-Low in Ductal Carcinoma In Situ of the Breast. Clinical Breast Cancer. 25(1). e79–e85.e1. 1 indexed citations
7.
Marta, Guilherme Nader, Marta Monteforte, Elisa Agostinetto, et al.. (2024). Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis. ESMO Open. 9(3). 102390–102390. 24 indexed citations
8.
Bernasconi, Alice, Peter Lucas, Marco Scutari, et al.. (2024). From Real-World Data to Causally Interpretable Models: A Bayesian Network to Predict Cardiovascular Diseases in Adolescents and Young Adults with Breast Cancer. Cancers. 16(21). 3643–3643. 1 indexed citations
9.
Zambelli, Alberto, Marina Elena Cazzaniga, Nicla La Verde, et al.. (2023). A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy. The Breast. 71. 113–121. 2 indexed citations
10.
Silvestri, Marco, Trung Nghia Vu, Federico Nichetti, et al.. (2023). Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma. Cancer Medicine. 12(8). 10156–10168. 7 indexed citations
11.
Trama, Annalisa, Alice Bernasconi, Laura Botta, et al.. (2022). COVID‐19 outbreak in Lombardy: Impact on reducing solid cancer diagnoses in 2020. International Journal of Cancer. 151(9). 1502–1511. 5 indexed citations
12.
Rose, Fiorenza De, Bruno Meduri, Maria Carmen De Santis, et al.. (2022). Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treatment Reviews. 109. 102434–102434. 29 indexed citations
13.
Cavallo, Anna, Eliana La Rocca, Serena Di Cosimo, et al.. (2021). Hypofractionated whole-breast radiotherapy in large breast size patients: is it really a resolved issue?. Medical Oncology. 38(9). 107–107. 4 indexed citations
14.
Pascual, Tomás, Mafalda Oliveira, Patricia Villagrasa, et al.. (2021). Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. npj Breast Cancer. 7(1). 145–145. 8 indexed citations
15.
Cosimo, Serena Di, Luca Porcu, Dominique Agbor‐Tarh, et al.. (2020). Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Research. 22(1). 115–115. 22 indexed citations
16.
Santis, Maria Carmen De, Eliana La Rocca, E. Meneghini, et al.. (2019). Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients. Clinical & Translational Oncology. 22(5). 786–792. 1 indexed citations
17.
Triulzi, Tiziana, Viola Regondi, Loris De Cecco, et al.. (2018). Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. British Journal of Cancer. 119(12). 1487–1494. 37 indexed citations
18.
Sonnenblick, Amir, Dominique Agbor‐Tarh, Ian Bradbury, et al.. (2017). Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Journal of Clinical Oncology. 35(13). 1421–1429. 106 indexed citations
19.
Cosimo, Serena Di, Sriram Sathyanarayanan, Johanna C. Bendell, et al.. (2014). Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. Clinical Cancer Research. 21(1). 49–59. 48 indexed citations
20.
Serra, Violeta, Ben Markman, Maurizio Scaltriti, et al.. (2008). NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. Cancer Research. 68(19). 8022–8030. 626 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beth Overmoyer Breakdown of academic impact, for papers by Kan Yonemori Breakdown of academic impact, for papers by Nina J. Karlin Breakdown of academic impact, for papers by Shenghui Tang Breakdown of academic impact, for papers by Ferry A.L.M. Eskens Breakdown of academic impact, for papers by Montserrat Muñoz-Mateu Breakdown of academic impact, for papers by Robert Justice Breakdown of academic impact, for papers by Marc Espié Breakdown of academic impact, for papers by Marek Z. Wojtukiewicz Breakdown of academic impact, for papers by Erica L. Mayer
Rankless by CCL
2026